TVTX - Travere Therapeutics, Inc.

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 5.26

Open

$ 5.36

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 5.22 - $ 5.55

52 Week Range

$ 5.12 - $ 22.75

Volume

1,220,072

Average Volume

Market Cap

390.65M

Beta (5Y Monthly)

$ 0.94

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-20-2024	12-31-2023	10-K
2	11-07-2023	09-30-2023	10-Q
3	08-03-2023	06-30-2023	10-Q
4	05-04-2023	03-31-2023	10-Q
5	02-23-2023	12-31-2022	10-K
6	10-27-2022	09-30-2022	10-Q
7	08-04-2022	06-30-2022	10-Q
8	05-05-2022	03-31-2022	10-Q
9	02-24-2022	12-31-2021	10-K
10	10-29-2021	09-30-2021	10-Q
11	07-29-2021	06-30-2021	10-Q
12	05-06-2021	03-31-2021	10-Q
13	03-01-2021	12-31-2020	10-K
14	11-05-2020	09-30-2020	10-Q
15	07-31-2020	06-30-2020	10-Q
16	05-11-2020	03-31-2020	10-Q
17	02-24-2020	12-31-2019	10-K
18	10-30-2019	09-30-2019	10-Q
19	08-06-2019	06-30-2019	10-Q
20	05-07-2019	03-31-2019	10-Q
21	02-26-2019	12-31-2018	10-K
22	11-01-2018	09-30-2018	10-Q
23	08-03-2018	06-30-2018	10-Q
24	05-01-2018	03-31-2018	10-Q
25	02-27-2018	12-31-2017	10-K
26	11-07-2017	09-30-2017	10-Q
27	08-09-2017	06-30-2017	10-Q
28	05-05-2017	03-31-2017	10-Q
29	03-01-2017	12-31-2016	10-K
30	11-04-2016	09-30-2016	10-Q
31	08-05-2016	06-30-2016	10-Q
32	05-05-2016	03-31-2016	10-Q
33	02-26-2016	12-31-2015	10-K
34	11-06-2015	09-30-2015	10-Q
35	08-10-2015	06-30-2015	10-Q
36	05-11-2015	03-31-2015	10-Q
37	03-11-2015	12-31-2014	10-K
38	11-13-2014	09-30-2014	10-Q
39	08-14-2014	06-30-2014	10-Q
40	05-15-2014	03-31-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Maintains Buy on Trave...
04/24/2024 18:38:30

HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...

CSL Vifor And Travere Therapeutics Granted...
04/24/2024 07:14:26

First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing autho...

Reported Earlier, Travere Therapeutics And...
04/19/2024 15:41:24

https://ec.europa.eu/transparency/documents-register/detail?ref=C(2024)2719&lang=en

Critical Insights From Travere Therapeutic...
04/17/2024 19:00:46

Wedbush Reiterates Outperform on Travere T...
04/17/2024 17:23:24

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $13 price target.

Travere Therapeutics To Present Abstracts ...
04/03/2024 20:46:33

Guggenheim Downgrades Travere Therapeutics...
03/27/2024 10:49:02

Guggenheim analyst Vamil Divan downgrades Travere Therapeutics (NASDAQ:TVTX) from Buy to Neutral.

Peeling Back The Layers: Exploring Travere...
03/13/2024 14:00:18

HC Wainwright & Co. Maintains Buy on Trave...
03/13/2024 13:45:33

HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $17 price target.

Travere Therapeutics Submits Supplemental ...
03/11/2024 11:11:57

Travere Therapeutics And CSL Vifor Announc...
02/23/2024 12:07:55

Deep Dive Into Travere Therapeutics Stock:...
02/16/2024 14:00:32

Wedbush Reiterates Outperform on Travere T...
02/16/2024 13:57:39

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $13 price target.

Travere Therapeutics Q4 Adj EPS $(0.94) Be...
02/15/2024 21:03:56

Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of ...

Earnings Scheduled For February 15, 2024
02/15/2024 10:17:01

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on rev...

Earnings Preview For Travere Therapeutics
02/14/2024 19:01:50

Travere Therapeutics Announces Licensing A...
01/25/2024 21:40:05

Travere Therapeutics, Inc., (NASDAQ:TVTX) announced that it has entered into an exclusive licensing agreement with Renalys Phar...

Cracking The Code: Understanding Analyst R...
01/18/2024 20:00:20

Piper Sandler Maintains Neutral on Travere...
01/18/2024 19:14:32

Piper Sandler analyst Nicole Gabreski maintains Travere Therapeutics (NASDAQ:TVTX) with a Neutral and raises the price targe...

Travere Therapeutics Ended 2023 With Appro...
01/08/2024 12:11:19